MX367376B - Formulas cristalinas de grapiprant. - Google Patents

Formulas cristalinas de grapiprant.

Info

Publication number
MX367376B
MX367376B MX2016011023A MX2016011023A MX367376B MX 367376 B MX367376 B MX 367376B MX 2016011023 A MX2016011023 A MX 2016011023A MX 2016011023 A MX2016011023 A MX 2016011023A MX 367376 B MX367376 B MX 367376B
Authority
MX
Mexico
Prior art keywords
grapiprant
crystalline
crystalline forms
substantially pure
group
Prior art date
Application number
MX2016011023A
Other languages
English (en)
Other versions
MX2016011023A (es
Inventor
NEWBOLD Tamara
Smith Melissa
Seekamp Chris
Wenslow Robert
Lu Xia
Original Assignee
Aratana Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aratana Therapeutics Inc filed Critical Aratana Therapeutics Inc
Publication of MX2016011023A publication Critical patent/MX2016011023A/es
Publication of MX367376B publication Critical patent/MX367376B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Led Devices (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Ceramic Products (AREA)
  • Inorganic Insulating Materials (AREA)

Abstract

La presente descripción proporciona una forma cristalina de grapiprant seleccionada del grupo que consiste en la Forma X, Forma X2, Forma X3, Forma F, Forma K, Forma L, Forma M y Forma N. Además se proporciona una composición farmacéutica, donde la composición comprende por lo menos una forma cristalina de grapiprant, y por lo menos un excipiente farmacéuticamente aceptable, donde la forma cristalina de grapiprant se selecciona del grupo que consiste en Forma X, Forma X2, Forma X3, Forma F, Forma K, Forma L, Forma M y Forma N. Otros aspectos de la descripción proporcionan un proceso para la preparación de una Forma A cristalina sustancialmente pura de grapiprant. El proceso comprende poner en contacto el grapiprant a temperatura ambiente con un solvente que comprende diclorometano y acetona para formar una solución saturada o casi saturada. Se forman cristales de la Forma A cristalina sustancialmente pura de grapiprant.
MX2016011023A 2014-03-06 2015-03-05 Formulas cristalinas de grapiprant. MX367376B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461949006P 2014-03-06 2014-03-06
US201461996961P 2014-07-30 2014-07-30
PCT/US2015/019043 WO2015134797A1 (en) 2014-03-06 2015-03-05 Crystalline forms of grapiprant

Publications (2)

Publication Number Publication Date
MX2016011023A MX2016011023A (es) 2016-11-28
MX367376B true MX367376B (es) 2019-08-16

Family

ID=54016295

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016011023A MX367376B (es) 2014-03-06 2015-03-05 Formulas cristalinas de grapiprant.
MX2018003837A MX388969B (es) 2014-03-06 2015-03-05 Formulas cristalinas de grapiprant.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018003837A MX388969B (es) 2014-03-06 2015-03-05 Formulas cristalinas de grapiprant.

Country Status (16)

Country Link
US (1) US9265756B2 (es)
EP (4) EP3511000B1 (es)
JP (2) JP6535683B2 (es)
KR (2) KR101697914B1 (es)
CN (11) CN107501262A (es)
AU (1) AU2015227064B2 (es)
CA (10) CA2997692A1 (es)
DK (3) DK3511000T3 (es)
ES (3) ES2919346T3 (es)
MX (2) MX367376B (es)
NZ (3) NZ733234A (es)
PL (3) PL3113773T3 (es)
PT (3) PT3295941T (es)
RU (1) RU2638931C1 (es)
TW (1) TWI537270B (es)
WO (1) WO2015134797A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12109218B2 (en) 2014-12-09 2024-10-08 Aratana Therapeutics, Inc. Compositions of grapiprant and methods for using the same
TWI664969B (zh) 2014-03-06 2019-07-11 雅瑞塔那醫療公司 格拉匹綸(ｇｒａｐｉｐｒａｎｔ)組合物及其使用方法
CN112292128A (zh) 2018-04-16 2021-01-29 阿瑞斯医疗有限公司 Ep4抑制剂和其用途
US20210315909A1 (en) * 2018-07-11 2021-10-14 Arrys Therapeutics, Inc. Polymorphic compounds and uses thereof
IL280051B2 (en) * 2018-07-11 2024-03-01 Arrys Therapeutics Inc EP4 inhibitors and their synthesis
US11254675B2 (en) * 2019-08-12 2022-02-22 Cadila Healthcare Limited Process for preparation of grapiprant
WO2021226162A1 (en) 2020-05-05 2021-11-11 Arrys Therapeutics, Inc. Ep4 antagonists and their use in the treatment of proliferative diseases
CN116283959A (zh) * 2021-12-10 2023-06-23 江苏慧聚药业股份有限公司 格拉匹纶新晶型及其制备

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
AU2006221699A1 (en) * 2005-03-11 2006-09-14 Pfizer Inc. Crystal forms of an imidazole derivative
EP2270000B1 (en) * 2005-05-23 2015-07-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
JP5069752B2 (ja) * 2006-12-15 2012-11-07 グラクソ グループ リミテッド Ｅｐ４受容体アゴニストとしてのベンズアミド誘導体
CN102149384B (zh) * 2008-08-14 2014-08-20 南京奥昭生物科技有限公司 作为ep4受体拮抗剂的杂环酰胺衍生物
CN103702995B (zh) 2011-05-18 2016-04-13 拉夸里亚创药株式会社 4-{[4-({[4-(2,2,2-三氟乙氧基)-1,2-苯并异噁唑-3-基]氧}甲基)哌啶-1-基]甲基}-四氢-2h-吡喃-4-羧酸的多晶型形式

Also Published As

Publication number Publication date
CA2997694A1 (en) 2015-09-11
NZ724923A (en) 2018-03-23
PL3295941T3 (pl) 2020-11-16
EP3511000A1 (en) 2019-07-17
CA2997697A1 (en) 2015-09-11
JP6535683B2 (ja) 2019-06-26
PT3511000T (pt) 2022-05-25
EP3113773A4 (en) 2017-05-10
US20150250774A1 (en) 2015-09-10
TWI537270B (zh) 2016-06-11
CN107400132A (zh) 2017-11-28
JP2018065819A (ja) 2018-04-26
PT3295941T (pt) 2020-08-25
WO2015134797A1 (en) 2015-09-11
CA2997746A1 (en) 2015-09-11
KR101697914B1 (ko) 2017-01-18
MX388969B (es) 2025-03-20
KR20170008889A (ko) 2017-01-24
CN110256426A (zh) 2019-09-20
CN107759590A (zh) 2018-03-06
KR101771385B1 (ko) 2017-08-24
CA2997692A1 (en) 2015-09-11
EP3295941A1 (en) 2018-03-21
CA3168877A1 (en) 2015-09-11
AU2015227064A1 (en) 2016-10-27
CA2997718A1 (en) 2015-09-11
EP3511000B1 (en) 2022-04-27
NZ733225A (en) 2018-03-23
EP3113773B1 (en) 2019-09-18
DK3113773T3 (da) 2019-11-18
DK3295941T3 (da) 2020-08-24
CA2997694C (en) 2021-04-06
CN107540671A (zh) 2018-01-05
KR20160106779A (ko) 2016-09-12
CN107759589A (zh) 2018-03-06
CA2941019A1 (en) 2015-09-11
CN107501262A (zh) 2017-12-22
EP3520790A1 (en) 2019-08-07
AU2015227064B2 (en) 2017-05-11
US9265756B2 (en) 2016-02-23
CA3105571A1 (en) 2015-09-11
ES2919346T3 (es) 2022-07-26
CN105764508A (zh) 2016-07-13
ES2755396T3 (es) 2020-04-22
PL3511000T3 (pl) 2022-08-22
PT3113773T (pt) 2019-11-12
PL3113773T3 (pl) 2020-05-18
CN107501263A (zh) 2017-12-22
EP3113773A1 (en) 2017-01-11
CN113087705A (zh) 2021-07-09
CA2997703A1 (en) 2015-09-11
NZ733234A (en) 2018-08-31
CN107573339A (zh) 2018-01-12
ES2816057T3 (es) 2021-03-31
CA2997741A1 (en) 2015-09-11
MX2016011023A (es) 2016-11-28
CN107759591A (zh) 2018-03-06
RU2638931C1 (ru) 2017-12-19
EP3295941B1 (en) 2020-07-22
JP2017507161A (ja) 2017-03-16
TW201538500A (zh) 2015-10-16
DK3511000T3 (da) 2022-05-30

Similar Documents

Publication Publication Date Title
NZ733234A (en) Crystalline forms of grapiprant
EA202090917A1 (ru) Получение псилоцибина, различных полиморфных форм, промежуточных соединений, составов и их применение
EP3031956B1 (en) Process for the preparation of ultra-high purity carbon monoxide
MY192824A (en) Compound targeting il-23a and tnf-alpha and uses thereof
NZ727392A (en) Methods of preparing substituted nucleotide analogs
HUE046658T2 (hu) Eljárás cukrosított oldat elõállítására biomassza nyersanyagként való felhasználásával, berendezés cukrosított oldat elõállítására
NZ778077A (en) Plinabulin compositions
MY194466A (en) Heterophasic polypropylene composition
MX360957B (es) Proceso de fabricación de adamantanamidas.
UA116825C2 (uk) Морфологічні форми гексадецилоксипропілових складних ефірів фосфонової кислоти і способи їх синтезу
MX2017007191A (es) Procedimiento de produccion de cristales de derivado de diazabiciclooctano y preparacion liofilizada estable.
IN2014MU00455A (es)
MX2015016571A (es) Revestimientos de geomembranas a altas temperaturas y composiciones de lote maestro.
PY1515461A (es) Derivados de Dihidropirrolopirimidina
PH12016501997A1 (en) Cycloalkyl-linked diheterocycle derivatives
PH12018500872A1 (en) Innovative preparation and crystallization of iosimenol
IL245260B (en) Non-aqueous crystalline form of cabazitaxel, process for its preparation and pharmaceutical compositions thereof
NZ733226A (en) Crystalline forms of grapiprant
GB2559718B (en) Novel crystalline form of tribenuron-methyl, process for preparation and use thereof
IN2013MU03508A (es)
IN2013MU02528A (es)
IN2014CH00444A (es)
GB201721201D0 (en) Process for preparing novel crystalline form of iodosulfuron-methyl-sodium and use
IN2014MU00565A (es)
IN2013CH01831A (es)

Legal Events

Date Code Title Description
FG Grant or registration